Education
About Us
Working with TipRanks
Follow Us
Clearpoint Neuro, Inc. (CLPT)
NASDAQ:CLPT
CLPT Stock Chart & Stats
$27.32
-$0.35(-2.27%)
At close: 4:00 PM EST
$27.32
-$0.35(-2.27%)
Day’s Range― - ―
52-Week Range$8.63 - $30.10
Previous CloseN/A
Volume88.39K
Average Volume (3M)948.45K
Market Cap
$267.86M
Enterprise Value$280.94M
Total Cash (Recent Filing)$45.92M
Total Debt (Recent Filing)$58.23M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
May 12, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding29,663,876
10 Day Avg. Volume948,036
30 Day Avg. Volume948,445
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)13.82
Price to Sales (P/S)10.48
P/FCF Ratio-15.84
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue7.60
Enterprise Value/Gross Profit12.38
Enterprise Value/Ebitda-12.54
Forecast
1Y Price Target
$25.00Price Target Upside-8.49% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.8
Revenue Forecast (FY)$55.50M
Bulls Say, Bears Say
Bulls Say
Balance SheetThe balance sheet is solid with over $20M of cash and no debt.
EarningsFunctional Neuro growth was strong at 43% year-over-year.
Partnership DevelopmentsThe partner business recently had significant developments that accelerate $100s of millions of revenue opportunities, with 70%+ gross margins.
Bears Say
Market Entry TimingRevenue opportunities from the partner business are expected to be on the market as early as late 2026.
ClearPoint Neuro News
CLPT FAQ
What was Clearpoint Neuro, Inc.’s price range in the past 12 months?
Clearpoint Neuro, Inc. lowest stock price was $8.63 and its highest was $30.10 in the past 12 months.
What is Clearpoint Neuro, Inc.’s market cap?
Clearpoint Neuro, Inc.’s market cap is $267.86M.
When is Clearpoint Neuro, Inc.’s upcoming earnings report date?
Clearpoint Neuro, Inc.’s upcoming earnings report date is May 12, 2026 which is in 49 days.
How were Clearpoint Neuro, Inc.’s earnings last quarter?
Clearpoint Neuro, Inc. released its earnings results on Mar 17, 2026. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.2 by -$0.06.
Is Clearpoint Neuro, Inc. overvalued?
According to Wall Street analysts Clearpoint Neuro, Inc.’s price is currently Overvalued.
Does Clearpoint Neuro, Inc. pay dividends?
Clearpoint Neuro, Inc. does not currently pay dividends.
What is Clearpoint Neuro, Inc.’s EPS estimate?
Clearpoint Neuro, Inc.’s EPS estimate is -0.26.
How many shares outstanding does Clearpoint Neuro, Inc. have?
Clearpoint Neuro, Inc. has 29,663,876 shares outstanding.
What happened to Clearpoint Neuro, Inc.’s price movement after its last earnings report?
Clearpoint Neuro, Inc. reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.2. Following the earnings report the stock price went down -13.934%.
Which hedge fund is a major shareholder of Clearpoint Neuro, Inc.?
Currently, no hedge funds are holding shares in CLPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ClearPoint Neuro Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (-8.49% Downside)
$25.00 (-8.49% Downside)
Blogger Sentiment
Bullish
CLPT Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 14.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.94%
12-Months-Change
Fundamentals
Return on Equity
-122.17%
Trailing 12-Months
Asset Growth
157.44%
Trailing 12-Months
Company Description
Clearpoint Neuro, Inc.
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
CLPT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed strong commercial and clinical momentum — year-over-year revenue growth, a significantly larger cash balance from recent financing, important regulatory clearances (PRISM 1.5T, CE for 3.X), an expanding partner and clinical footprint (>60 partners, 25+ trials), and an operational roadmap (CAL facility, robotics). At the same time, the business is managing notable near-term headwinds from increased operating expenses (notably G&A +38%), elevated cash burn from operations ($23.9M), higher interest expense following financing, acquisition-related one-time costs and assumed liabilities, and some removed upside due to stricter FDA positioning on rare-disease approval pathways. Management provided a constructive 2026 revenue guide ($52M–$56M) but acknowledged regulatory and integration risks that could affect timing of upside.View all CLPT earnings summariesCLPT Stock 12 Month Forecast
Average Price Target
$25.00
▼(-8.49% Downside)
Technical Analysis
Ownership Overview
3.29% Insiders
8.63% Mutual Funds
8.39% Other Institutional Investors
71.19% Public Companies and Individual Investors